Regeneron's Eylea still racing ahead; Strong Opsumit launch boosts Actelion forecast; Diabetes texts kept patients on meds;

> Regeneron's ($REGN) Eylea drug continues to grow by leaps and bounds, with $610 million in fourth quarter sales, up from $415 million a year ago. Report

> The Swiss drugmaker Actelion hiked its 2014 earnings forecast after its new treatment for pulmonary arterial hypertension, Opsumit, got off to a better-than-expected start. Report

> A 6 month experiment in diabetes management, using mobile communications including texts, boosted prescription costs because of better drug adherence, but saved more than $32,000 on doctor visits, ER trips and other services. Report

> Seattle Genetics ($SGEN) promoted two commercial executives--Chris Boerner, to EVP, Commercial; and Charles (Chip) Romp to SVP, Sales--and added David Fontana as VP of portfolio management and Adcetris program manager. Release

> Keryx Biopharmaceuticals brought on Greg Madison as EVP and chief operating officer; he will be charged with building a commercial organization to support the potential launch of Zerenex, a drug for kidney patients. Release

And Finally... Some doctors argue caution in using new obesity drugs from Arena Pharmaceuticals ($ARNA) and Vivus ($VVUS). Report

Suggested Articles

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opidivo has broken through with two potentially practice-changing trials.

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

The Tecentriq-Avastin-chemo cocktail did slightly better in PD-L1-positive patients but still failed to cross the statistical significance bar.